|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Rat TNFSF14 ORF mammalian expression plasmid, C-GFPSpark tag||RG80175-ACG|
|Rat TNFSF14 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80175-ACR|
|Rat TNFSF14 ORF mammalian expression plasmid, C-Flag tag||RG80175-CF|
|Rat TNFSF14 ORF mammalian expression plasmid, C-His tag||RG80175-CH|
|Rat TNFSF14 ORF mammalian expression plasmid, C-Myc tag||RG80175-CM|
|Rat TNFSF14 ORF mammalian expression plasmid, C-HA tag||RG80175-CY|
|Rat TNFSF14 Gene cDNA clone plasmid||RG80175-G|
|Rat TNFSF14 ORF mammalian expression plasmid, N-Flag tag||RG80175-NF|
|Rat TNFSF14 ORF mammalian expression plasmid, N-His tag||RG80175-NH|
|Rat TNFSF14 ORF mammalian expression plasmid, N-Myc tag||RG80175-NM|
|Rat TNFSF14 ORF mammalian expression plasmid, N-HA tag||RG80175-NY|
|Rat TNFSF14 natural ORF mammalian expression plasmid||RG80175-UT|
|Learn more about expression Vectors|
LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble nonsignaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+ and CD8+ T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.